Showing 1371-1380 of 1621 results for "".
- Is Undergraduate Ophthalmology Teaching in the United Kingdom Still Fit for Purpose?https://modernod.com/news/is-undergraduate-ophthalmology-teaching-in-the-united-kingdom-still-fit-for-purpose/2479479/An editorial in the publication Eye examines the reasons behind why an increasing number of junior doctors and general practitioners in the UK are losing confidence in their ophthalmic knowledge. Such factors cited in the d
- Glaucoma UK Launches New Services Booklet for People Living With Glaucomahttps://modernod.com/news/glaucoma-uk-launches-new-services-booklet-for-people-living-with-glaucoma/2478926/Glaucoma UK is launching a new booklet to highlight the services it can offer to people with glaucoma, and the health care professionals looking after them. With an estimated 700,000 people in the UK living with the d
- Conbercept Treatment of Wet AMD Completes 36-Week Primary Endpoint Visits of Phase 3 Trialhttps://modernod.com/news/conbercept-treatment-of-wet-amd-completes-36-week-primary-endpoint-visits-of-phase-3-trial/2478698/China-based Chengdu Kanghong Pharmaceutical Group announced a key development milestone of its key product conbercept last month. Kanghong is seeking global approval of conbercept by undertaking a multicenter, multinational, d
- ReVision Therapeutics Announces License With Cornell to Develop Treatment for Stargardt Diseasehttps://modernod.com/news/revision-therapeutics-announces-license-with-cornell-to-develop-treatment-for-stargardt-disease/2478230/ReVision Therapeutics announced that it has signed an exclusive license agreement with Cornell University for the development and commercialization of Cornell’s proprietary technology for the treatment of Stargardt disease, a genetic d
- Aldeyra Therapeutics to Provide Update on Late-Stage Clinical Development Pipeline at 2020 Research & Development Dayhttps://modernod.com/news/aldeyra-therapeutics-to-provide-update-on-late-stage-clinical-development-pipeline-at-2020-research-development-day/2477322/Aldeyra Therapeutics on Monday hosted the 2020 Research & Development Day (R&D Day) with investors and financial analysts in New York City to present recent clinical development updates and market opportun
- Antibody-based eye drops show promise for treating dry eye diseasehttps://modernod.com/news/antibody-based-eye-drops-show-promise-for-treating-dry-eye-disease/2477005/Researchers at the University of Illinois at Chicago are the first to identify the presence of a specific type of antibody, called anti-citrullinated protein autoantibodies, or ACPAs, in human tear fluid. They are also the first to demonstrate that patients with dry eye d
- Sight Sciences Raises $56M to Lead the Development of MIGS Market and Procedure-Based Dry Eye Markethttps://modernod.com/news/sight-sciences-raises-56m-to-lead-the-development-of-migs-market-and-procedure-based-dry-eye-market/2476848/Sight Sciences announced the closing of $31 million in Series D Preferred Stock financing. MidCap Financial and Sight Sciences entered into a $25 million debt facility earlier in 2019. The $56 million
- Aggressive Steroid Therapy Improves Visual Outcomes in Vogt-Koyanagi-Harada Diseasehttps://modernod.com/news/aggressive-steroid-therapy-improves-visual-outcomes-in-vogt-koyanagi-harada-disease/2480135/Aggressive treatment beginning with pulsed intravenous corticosteroids appears to improve visual outcomes of new-onset acute Vogt-Koyanagi-Harada (VKH) disease, researchers from Japan report, according to a report in Medscape. VKH d
- Oculis Prices $110 Million Financing to Accelerate Privosegtor Developmenthttps://modernod.com/news/oculis-prices-110-million-financing-to-accelerate-privosegtor-development/2484298/Oculis announced the pricing of offerings of an aggregate of 5,432,098 of its ordinary shares at a price of $20.25 per share for total gross proceeds of $110 million. The net proceeds from the financing will be used to advance and accelerate the d
- Harrow Acquires US Commercial Rights to Byqlovi for Postoperative Inflammation and Painhttps://modernod.com/news/harrow-acquires-us-commercial-rights-to-byqlovi-for-postoperative-inflammation-and-pain/2482841/Harrow and Taiwan-based Formosa Pharmaceuticals announced a licensing agreement in which Harrow has acquired the exclusive US commercial rights for Byqlovi (clobetasol propionate ophthalmic suspension) 0.05%. Financial terms of the deal were not d